# A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

> **NCT03700359** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Anlotinib Hydrochloride
- **DRUG:** Lobaplatin
- **DRUG:** Etoposide

## Key facts

- **NCT ID:** NCT03700359
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2020-11-29
- **Final completion:** 2021-11-29
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03700359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03700359, "A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03700359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*